FDA told Novid Group its OTC nasal spray, novid NASAL SPRAY, is an unapproved new drug and misbranded.
What happened
FDA reviewed the company's website at https://getnovid.com/ on October 12, 2023, where the product is offered for sale. FDA found the spray marketed as a combination antihistamine and nasal decongestant, with labeled active ingredients sodium chloride and organic fulvic acids, which are not permitted under the OTC cold, cough and allergy monograph (FDA's rulebook for such products). FDA also found website claims that the spray protects against catching colds or viral infections and boosts immune activity.
What FDA found
The spray is a new drug sold without an FDA-approved application.
Section 505(a), 21 U.S.C. 355(a)Its active ingredients, sodium chloride and organic fulvic acids, are not allowed for this kind of OTC product under the cold, cough and allergy monograph.
Section 505G, 21 U.S.C. 355hLabeling claims that it protects people from catching colds or viral infections are not permitted under that monograph.
Section 505G, 21 U.S.C. 355h; 21 CFR 201.128Claims that it reduces inflammation and enhances immune cell activity are not permitted under that monograph.
Section 505G, 21 U.S.C. 355hThe product is misbranded because it does not meet the requirements for marketing without an approved application.
Section 502(ee), 21 U.S.C. 352(ee)Shipping the product across state lines is prohibited.
Sections 301(a) and 301(d), 21 U.S.C. 331(a) and 331(d)
What FDA wants
FDA asks the company to write within 15 working days describing the specific steps taken to correct the violations, with an explanation of how recurrence will be prevented and copies of related documents. If corrections cannot be finished in that time, the company must say why and give a completion date; the response goes by email to FDAAdvisory@fda.hhs.gov.
Who should pay attention
- retailers and online marketplaces that list this spray
- brands selling OTC nasal sprays with non-monograph ingredients
- companies making infection-prevention or immune-boosting claims for consumer health products
This is a summary. Read the original letter on fda.gov.